Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib
Oncology · 2024
DOI: 10.1159/000540542 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Zhijing Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Affiliated Hospital of Putian University, Pu Tian, China. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, United States Food and Drug Administration, Databases, Factual. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Introduction
Asciminib is primarily utilized for treating Philadelphia chromosome-positive chronic myeloid leukemia in its chronic phase among patients harboring the T315I mutation or those who have been previously treated with at least two tyrosine kinase inhibitors. The safety profile of asciminib across a broad patient population over an extended timeframe remains unverified. This study uses a real-world pharmacovigilance database to evaluate the adverse events (AEs) linked with asciminib, providing valuable insights for clinical drug safety.
Methods
Data from the FDA Adverse Event Reporting System (FAERS) database, spanning from October 2021 to December 2023, served as the basis for this analysis. The extent of disproportional events was assessed using sophisticated metrics such as the reporting odds ratio, proportional reporting ratio, information component, and empirical Bayesian geometric mean.
Results
Within the specified period, the FAERS database documented 3,913,574 AE reports, with asciminib being associated with 966 incidents. Reactions to asciminib spanned 27 system organ categories. Utilizing four distinct analytical algorithms, 663 significant preferred terms exhibiting disproportional frequencies were identified. Notably, this investigation uncovered 26 significant AEs linked to off-label asciminib use, encompassing conditions such as gynecomastia, nephrotic syndrome, orchitis, pyelonephritis, hepatotoxicity, and pancreatitis. The median onset time for asciminib-related AEs was 52.5 days, ranging from 17 to 122.75 days.
Conclusion
The study sheds light on additional potential AEs associated with asciminib use, warranting further research to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Affiliated Hospital of Putian University, Pu Tian, China.
- Department of Orthopedics Institute, Fuzhou Second General Hospital, Fuzhou, China.
- Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
- Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
- Department of Pharmacy, Pingtan Comprehensive Experimental Area Hospital, Pingtan Comprehensive Experimental Area, Fuzhou, China.
- Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.
Zitieren
APA
Liu, Z., Wu, D., Ke, C., Nian, Q., Chen, Y., Huang, Y., & Chen, M. (2024). Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib. Oncology. https://doi.org/10.1159/000540542
Vancouver
Liu Z, Wu D, Ke C, Nian Q, Chen Y, Huang Y, et al. Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib. Oncology. 2024. doi:10.1159/000540542
BibTeX
@article{Liu2024,
author = {Liu, Zhijing and Wu, Dongzhi and Ke, Chengjie and Nian, Qichun and Chen, Yan and Huang, Yaping and Chen, Maohua},
title = {Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib},
journal = {Oncology},
year = {2024},
doi = {10.1159/000540542}
}
EUVIMED